Thursday, April 23, 2020 3:51:54 PM
Thanks for getting back to me. I recommend that SCYX issue a good-will corporate update ASAP, to calm your plunging PPS.
I also recommend that for future Warrants, to the extent there are remaining issued Warrants, they be reduced 1-for-1 when the related Common Shares are sold.
Your press release on Apr 21 reported very exciting news. This typically would attract new buyers & rewards existing Shareholders. However, the PPS has dropped around -28% since Apr 21. WHY is this?
Going forward, SCYX really needs to craft a better 1-for-1 warrants policy. The long term investors are getting severely punished by your last “selective” Public Offering Warrants.
There appears to be a strategic round trip strategy in-play at the $1.05+ to $1.10+ PPS levels. The Offering purchasers sell massive amounts of the Offering $.90 Common Shares because the 1.10 Warrants can, in the future, replenish shares sold. Also, If desirable, these same purchasers buy/increase the Common Shares when the PPS subsequently seems to bottom.
The aforementioned Warrant Holders are making huge profits by selling Common Shares (per above) while maintaining all of their Warrants. This massive selling precipitates anger & or panic selling to further plunge the PPS. To add insult to injury, at the bottoming of the PPS, Common Shares can be bought back by the selective Public Offering purchasers.
It should be noted that your future funding needs are compromised by lower (than justifiable) PPS because of the above matters.
Please forward this email to your Management.
Recent SCYX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 10:48:23 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 02:09:53 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:41:39 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 09:32:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:03:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:01:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/30/2024 09:01:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 02:53:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 09:01:09 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/28/2023 09:05:54 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/28/2023 09:05:51 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/28/2023 05:15:14 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2023 10:09:33 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/13/2023 09:45:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:01:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 01:15:16 PM
- SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance • GlobeNewswire Inc. • 09/28/2023 12:31:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2023 12:32:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:01:54 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 07/18/2023 08:28:34 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM